GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zura Bio Ltd (STU:94E) » Definitions » Other Current Payables

Zura Bio (STU:94E) Other Current Payables : €0.00 Mil (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Zura Bio Other Current Payables?

Zura Bio's Other Current Payables for the quarter that ended in Dec. 2024 was €0.00 Mil.


Zura Bio Other Current Payables Historical Data

The historical data trend for Zura Bio's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zura Bio Other Current Payables Chart

Zura Bio Annual Data
Trend Mar22 Dec23 Dec24
Other Current Payables
- - -

Zura Bio Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Zura Bio Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.


Zura Bio Other Current Payables Related Terms

Thank you for viewing the detailed overview of Zura Bio's Other Current Payables provided by GuruFocus.com. Please click on the following links to see related term pages.


Zura Bio Business Description

Traded in Other Exchanges
Address
1489 W. Warm Springs Road, Suite 110, Henderson, NV, USA, 89014
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.

Zura Bio Headlines

No Headlines